Photodynamic therapy with verteporfin: A new treatment in ophthalmology

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Seminars in Ophthalmology

• Publication date

  2001-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1076/soph.16.4.201.10298PMID 15513441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics of Verteporfin

  2002cited by this paper
• Photodynamic effects on choroidal neovascularization and physiological choroid.

  2002cited by this paper
• Photodynamic Therapy in Large Choroidal Hemangioma: Along-term Evaluation

  2002cited by this paper
• A Prospective Randomized Trial Comparing the Standard Regimen in Photodynamic Therapy (PDT) to Earlier / Less Frequent Retreatments

  2002cited by this paper
• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5

  2002cited by this paper
• Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results.

  2002cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.

  2002cited by this paper
• Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy

  2001cited by this paper
• Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

  2001cited by this paper
• CLINICOPATHOLOGIC STUDIES OF AGE-RELATED MACULAR DEGENERATION WITH CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION TREATED WITH PHOTODYNAMIC THERAPY

  2001cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

  2001cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin - 1-year results of a randomized clinical trial - VIP report no. 1

  2001cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

  2001cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

  2001cited by this paper
• TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP. PHOTODYNAMIC THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH VERTEPORFIN: TWO-YEAR RESULTS OF 2 RANDOMIZED CLINICAL TRIALS-TAP REPORT 2

  2001cited by this paper
• [Choroidal changes after photodynamic therapy (PDT). A two-year follow-up study of 38 patients].

  2000cited by this paper
• A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

  2000cited by this paper
• Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

  1999cited by this paper
• Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.

  1999cited by this paper
• Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.

  1999cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

  1999cited by this paper
• Photophysical and photobiological processes in the photodynamic therapy of tumours.

  1997cited by this paper
• Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates.

  1997cited by this paper
• Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye.

  1997cited by this paper
• Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization.

  1996cited by this paper
• Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

  1996cited by this paper
• Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors.

  1996cited by this paper
• Vascular Effects of Photodynamic Therapy

  1996cited by this paper
• In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization

  1995cited by this paper
• Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin.

  1995cited by this paper
• Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered Benzoporphyrin

  1995cited by this paper
• Vascular targeting in photodynamic occlusion of subretinal vessels.

  1994cited by this paper
• Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin.

  1994cited by this paper
• Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative.

  1994cited by this paper
• LIPOSOMAL DELIVERY OF A PHOTOSENSITIZER, BENZOPORPHYRIN DERIVATIVE MONOACID RING A (BPD), TO TUMOR TISSUE IN A MOUSE TUMOR MODEL

  1993cited by this paper
• HOW DOES PHOTODYNAMIC THERAPY WORK?

  1992cited by this paper
• Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents.

  1992cited by this paper
• Photodynamic therapy of cancer.

  1988cited by this paper
• Lipoprotein Receptors and Endothelial Cells

  1988cited by this paper
• Preliminary studies on a more effective phototoxic agent than hematoporphyrin.

  1987cited by this paper
• SITES OF PHOTOSENSITIZATION BY DERIVATIVES OF HEMATOPORPHYRIN

  1986cited by this paper
• Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells.

  1985cited by this paper
• Photodynamic therapy of malignant tumours.

  1972cited by this paper
• FURTHER EVALUATION OF THE USE OF HEMATOPORPHYRIN DERIVATIVE AS A NEW AID FOR THE ENDOSCOPIC DETECTION OF MALIGNANT DISEASE.

  1964cited by this paper

• Glow in the dark tumor: Enhanced near-IR visualization and destruction of cancer with a self-quenched theranostic.

  2025cites this paper
• HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver

  2025cites this paper
• Design and Combinatorial Synthesis of Biomimetic Multivariate Metal-Organic Frameworks for Efficient Drug Loading.

  2025cites this paper
• Natural and synthetic compounds targeting ferroptosis in esophageal squamous cell carcinoma: Research progress and application potential.

  2025cites this paper
• Hippo pathway effectors are associated with glioma patient survival, control cell proliferation and sterol metabolism through TEAD3

  2025cites this paper
• Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells.

  2024cites this paper
• Strategies that regulate Hippo signaling pathway for novel anticancer therapeutics.

  2024cites this paper
• A comprehensive review on carbon quantum dots as an effective photosensitizer and drug delivery system for cancer treatment

  2023cites this paper
• Current Management of Subretinal Hemorrhage in Neovascular Age-Related Macular Degeneration

  2023cites this paper
• Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases.

  2023cites this paper
• Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases

  2023cites this paper
• Functions of Yes-association protein (YAP) in cancer progression and anticancer therapy resistance

  2022cites this paper
• Neovascularization-directed bionic eye drops for noninvasive renovation of age-related macular degeneration

  2022cites this paper
• One-Step Aqueous Synthesis of Anionic and Cationic AgInS2 Quantum Dots and Their Utility in Improving the Efficacy of ALA-Based Photodynamic Therapy

  2022cites this paper
• An update in clinical utilization of photodynamic therapy for lung cancer

  2021cites this paper
• Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo

  2021cites this paper
• Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4.

  2021cites this paper
• The Hippo Signaling Pathway in Drug Resistance in Cancer

  2021cites this paper
• Yes-Associated Protein in Atherosclerosis and Related Complications: A Potential Therapeutic Target That Requires Further Exploration

  2021cites this paper
• Does Mechanocrine Signaling by Liver Sinusoidal Endothelial Cells Offer New Opportunities for the Development of Anti-fibrotics?

  2020cites this paper
• Osteoprotegerin promotes intimal hyperplasia and contributes to in-stent restenosis: Role of an αVβ3/FAK dependent YAP pathway.

  2020cites this paper
• Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells

  2020cites this paper
• The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.

  2019cites this paper
• Differential gene expression induced by Verteporfin in endometrial cancer cells

  2019cites this paper
• Helicobacter pylori‐induced YAP1 nuclear translocation promotes gastric carcinogenesis by enhancing IL‐1β expression

  2019cites this paper
• Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1

  2019cites this paper
• A brief review: some compounds targeting YAP against malignancies.

  2019cites this paper
• ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity

  2019cites this paper
• The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype

  2019cites this paper
• Ubiquitination‑deubiquitination in the Hippo signaling pathway (Review).

  2019cites this paper
• YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis.

  2018cites this paper
• Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

  2018cites this paper
• Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway

  2018cites this paper
• Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.

  2018cites this paper
• Using X-rays in photodynamic therapy: an overview

  2018cites this paper
• Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound.

  2017cites this paper
• Photodynamic antimicrobial chemotherapy for pathogenic vibrio control in prawn hatcheries

  2017cites this paper
• Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells

  2017cites this paper
• Ciblage thérapeutique de la voie Hippo pour le traitement des cancers mammaires chez la chienne

  2017cites this paper
• Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ.

  2017cites this paper
• Targeting YAP in malignant pleural mesothelioma

  2017cites this paper
• Cell reactions and immune responses to photodynamic therapy in oncology.

  2016cites this paper
• YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis.

  2016cites this paper
• Requirement and Function of Hippo Pathway Signaling in the Mammalian Gastrointestinal Tract: A Dissertation

  2016cites this paper
• Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration*

  2016cites this paper
• NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

  2015cites this paper
• YAP and TAZ are Mechanoregulators of TGF-β-Smad Signalling and Fibrogenesis

  2015cites this paper
• Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis

  2015cites this paper
• Characterizing low fluence thresholds for in vitro photodynamic therapy.

  2015cites this paper
• Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors

  2015cites this paper
• Biology of advanced uveal melanoma and next steps for clinical therapeutics

  2014cites this paper
• Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

  2014cites this paper
• Photodynamic Therapy: Current Status and Future Directions

  2014cites this paper
• Retinal injury thresholds for 532, 578, and 630 nm lasers in connection to photodynamic therapy for choroidal neovascularization

  2014cites this paper
• mTHPC mediated PDT of Head and Neck Cancer, Modifying pharmacokinetics using liposomal drug carriers

  2014cites this paper
• Proliferation and survival mechanisms in soft tissue sarcoma and glioblastoma tumors

  2014cites this paper
• Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study.

  2014cites this paper
• Vergleichende Biokompatibilitätsanalyse von Trägermaterialien zur Transplantation okulaerer Zellen

  2013cites this paper
• -Alkylpyridylporphyrins N and Phototoxicity of Zn(II) Cellular Uptake, Subcellular Localization, Effect of Molecular Characteristics on

  2013cites this paper
• Effect of Molecular Characteristics on Cellular Uptake, Subcellular Localization, and Phototoxicity of Zn(II) N-Alkylpyridylporphyrins*

  2013cites this paper
• Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma

  2013cites this paper
• The Hippo pathway and human cancer

  2013cites this paper
• Animal Models to Evaluate Ocular Nanoparticular Drug Delivery Systems

  2012cites this paper
• Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

  2012cites this paper
• Quit your YAPing: a new target for cancer therapy.

  2012cites this paper
• Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin*

  2010cites this paper
• Measurements of retinal temperature increase during photodynamic therapy for choroidal neovascularization

  2010cites this paper
• Anti-VEGF agents for age-related macular degeneration

  2010cites this paper
• Age-related macular degeneration (AMD); From pathogenesis and approved therapies to proposed treatments for prevention

  2008cites this paper
• RPE transplantation and its role in retinal disease.

  2007cites this paper
• Hexyl‐aminolevulinate‐mediated photodynamic therapy: How to spare normal urothelium. An in vitro approach

  2007cites this paper
• Detection of ROS in Cell During Photodynamic Therapy Applying Fluorescence Microscopy

  2007cites this paper
• Theoretical investigation of thermal retinal response to photodynamic therapy or choroidal neovascularization

  2007cites this paper
• Receptor-mediated DNA-targeted photoimmunotherapy.

  2006cites this paper
• Common Visual Problems: Symptoms and Treatment, Part II

  2005cites this paper